Abstract
This study aims to create a platelet donor database with detailed HLA epitope typing in the Jining area to serve as a foundation for treating refractory thrombocytopenia patients. HLA-A and -B epitope phenotype data were collected from 565 unrelated healthy donors. Using PCR-SSP, 73 distinct HLA-A and -B phenotypes were identified, including 55 with a frequency greater than 0.003. The results showed that a database of 565 donors could achieve an 84.20% matching coverage for patients requiring cross-reactive group (CREG) matching. This study establishes a regional donor database that facilitates safer and more efficient platelet transfusions for patients with platelet refractoriness.
Introduction
Patients requiring frequent platelet transfusions, such as those with severe blood disorders or cancers, often develop Platelet Transfusion Refractoriness (PTR). This condition occurs when the recipient's immune system produces antibodies against Human Leukocyte Antigens (HLA) on donor platelets. While full HLA-antigen matching is the gold standard for treatment, the high polymorphism of HLA makes finding perfect matches in small pools nearly impossible. Epitope matching, which focuses on specific molecular "fingerprints" (epitopes) recognized by the immune system, offers a more efficient alternative.
Methodology
The researchers established a regional database in Jining, China, using the following steps:
- Genotyping: PCR-SSP (Sequence-Specific Primer) technology was used to detect seven specific CREG public epitopes on the HLA-A and HLA-B loci of 565 healthy donors.
- Statistical Modeling: The Expectation-Maximization (EM) algorithm estimated epitope frequencies. Regression equations were derived to calculate the probability ($P$) of finding a match relative to the donor pool size ($N$).
- Database Construction: A searchable system was created integrating donor HLA epitope profiles and ABO blood types.
- Clinical Validation: 44 PTR patients were tested against the database using solid-phase agglutination to confirm compatibility.
Results and Analysis
The study identified 73 HLA-A and -B epitope phenotypes, with the 55 most common accounting for 96.81% of the population.
Matching Probability
Statistical analysis demonstrated that the probability of finding a compatible donor increases significantly with the size of the donor pool, particularly for higher-frequency phenotypes.
With the established pool of 565 donors, the overall matching probability reached 84.20%. This highlights the efficiency of epitope matching; traditional antigen matching would require a pool orders of magnitude larger to achieve similar coverage.
ABO Compatibility Considerations
When identical ABO-type transfusions are required, the effective donor pool size decreases, impacting the matching probability. The study modeled these variations to ensure the database remains robust under stricter clinical requirements.
Clinical Outcomes
In the validation cohort, 88.64% (39 out of 44) of PTR patients successfully found a compatible donor. Patients receiving epitope-matched platelets showed significant clinical improvement, including reaching target platelet counts and relief from bleeding symptoms.
Discussion
The "Negative Epitope" strategy is central to this success: patients lacking a specific epitope must receive platelets from donors who also lack it. This logic provides greater flexibility than full antigen matching. Furthermore, the regional focus ensures the donor pool reflects the specific HLA distribution of the local population, optimizing resource allocation.
Conclusion
The establishment of the Jining HLA epitope donor database demonstrates that epitope-level matching is a clinically effective and logistically superior alternative to traditional antigen matching for PTR patients. Future work will focus on expanding the donor pool and refining PCR-SSP methods to include a broader range of epitopes.
Summary updated